Eloxx Pharmaceuticals Inc Quick Ratio (ELOX) starting from the first quarter 2026 to first quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Eloxx Pharmaceuticals Inc   (NASDAQ: ELOX)

Eloxx Pharmaceuticals Inc 's Quick Ratio

ELOX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Eloxx Pharmaceuticals Inc 's Cash & cash equivalent grew by 32.98 % in the Q1 2026 sequentially, while Current Liabilities decreased, this led to improvement in Eloxx Pharmaceuticals Inc 's Quick Ratio to 1.49, Quick Ratio remained below Eloxx Pharmaceuticals Inc average.

Within Biotechnology & Pharmaceuticals industry 61 other companies have achieved higher Quick Ratio than Eloxx Pharmaceuticals Inc in first quarter 2026. While Quick Ratio total ranking has improved so far during the Q1 2026 to 811, from total ranking in the fourth quarter 2025 at 2882.

Explain Quick Ratio?
How much Cash & cash equivalents ELOX´s has?
What are ELOX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ELOX Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1
Y / Y Current Liabilities Change -77.31 % -25.61 % 8.24 % 6.43 % -1.99 %
Y / Y Cash & cash equivalent Change 29.75 % -75.09 % -80.55 % -85.59 % -87.67 %
Quick Ratio MRQ 1.49 0.28 0.2 0.21 0.26
ELOX's Total Ranking # 811 # 2882 # # #
Seq. Current Liabilities Change -75.18 % -26.8 % 13.04 % 10.46 % -18.61 %
Seq. Cash & cash equivalent Change 32.98 % 0.21 % 10.25 % -11.68 % -74.47 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 62
Healthcare Sector # 314
Overall Market # 811


Quick Ratio Statistics
High Average Low
14.56 2.97 0.17
(Jun 30 2018)   (Dec 31 2012)




Financial Statements
Eloxx Pharmaceuticals Inc 's Current Liabilities $ 4 Millions Visit ELOX's Balance sheet
Eloxx Pharmaceuticals Inc 's Cash & cash equivalent $ 6 Millions Visit ELOX's Balance sheet
Source of ELOX's Sales Visit ELOX's Sales by Geography


Cumulative Eloxx Pharmaceuticals Inc 's Quick Ratio

ELOX's Quick Ratio for the trailling 12 Months

ELOX Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months
Y / Y Current Liabilities TTM Growth -20.95 % -3.9 % 22.47 % 45.03 % 54.26 %
Y / Y Cash & cash equivalent TTM Growth -74.27 % -83.45 % -75.69 % -67.79 % -58.83 %
Quick Ratio TTM 0.31 0.23 0.39 0.63 0.95
Total Ranking TTM # 2048 # 3029 # # #
Seq. Current Liabilities TTM Growth -18.12 % -6.87 % 2.12 % 1.51 % -0.46 %
Seq. Cash & cash equivalent TTM Growth 7.76 % -43.42 % -37.32 % -32.67 % -30.7 %

Quick ratio ranking by company, industry and sector >> Back to ELOX Financial Strength Comparisons >> Go to Compare ELOX Quick Ratio to its Competitors

On the trailing twelve months basis ELOX Cash & cash equivalent grew by 29.75 % in Q1 2026 year on year, while Current Liabilities dropped to $4 millions, this led to increase in in Eloxx Pharmaceuticals Inc 's Quick Ratio to 0.31, Quick Ratio remained below ELOX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 77 other companies have achieved higher Quick Ratio than Eloxx Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 2048, from total ranking during the twelve months ending fourth quarter 2025 at 3029.

Explain Quick Ratio?
How much Cash & cash equivalents ELOX´s has?
What are ELOX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 78
Healthcare Sector # 481
Within the Market # 2048


trailing twelve months Quick Ratio Statistics
High Average Low
8.7 3.94 0.23
(Sep 30 2018)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Prime Medicine Inc   3.73 $ 135.497  Millions$ 36.289  Millions
Immunocore Holdings Plc  3.52 $ 844.896  Millions$ 240.113  Millions
Kodiak Sciences Inc   3.42 $ 169.530  Millions$ 49.573  Millions
Cardiff Oncology Inc   3.33 $ 46.056  Millions$ 13.817  Millions
Editas Medicine Inc   3.11 $ 123.648  Millions$ 39.779  Millions
Vericel Corporation  3.08 $ 145.340  Millions$ 47.155  Millions
Humacyte Inc   3.00 $ 48.539  Millions$ 16.187  Millions
Sutro Biopharma Inc   2.86 $ 202.558  Millions$ 70.811  Millions
Cabaletta Bio Inc   2.81 $ 116.635  Millions$ 41.507  Millions
Aligos Therapeutics Inc   2.80 $ 54.909  Millions$ 19.628  Millions
Adaptive Biotechnologies Corporation  2.51 $ 218.334  Millions$ 87.011  Millions
Iovance Biotherapeutics inc   2.48 $ 313.443  Millions$ 126.521  Millions
Novavax inc   2.31 $ 790.332  Millions$ 342.461  Millions
C4 Therapeutics Inc   2.25 $ 61.274  Millions$ 27.249  Millions
Moderna Inc   2.17 $ 5,205.000  Millions$ 2,395.000  Millions
Regenxbio Inc   2.12 $ 150.491  Millions$ 71.110  Millions
Exelixis Inc   2.10 $ 777.207  Millions$ 370.975  Millions
Quince Therapeutics Inc   2.07 $ 18.163  Millions$ 8.768  Millions
Autolus Therapeutics Plc  2.06 $ 130.951  Millions$ 63.599  Millions
Mink Therapeutics Inc   2.02 $ 9.526  Millions$ 4.718  Millions
Tarsus Pharmaceuticals Inc   2.00 $ 286.540  Millions$ 143.508  Millions
Adma Biologics Inc   1.91 $ 138.153  Millions$ 72.365  Millions
Vivosim Labs Inc   1.80 $ 5.024  Millions$ 2.785  Millions
Dyadic International Inc   1.76 $ 5.608  Millions$ 3.184  Millions
Calidi Biotherapeutics Inc   1.73 $ 6.631  Millions$ 3.836  Millions
Passage Bio Inc   1.66 $ 33.336  Millions$ 20.104  Millions
Neurocrine Biosciences Inc   1.58 $ 1,316.200  Millions$ 831.700  Millions
Jasper Therapeutics Inc   1.57 $ 14.144  Millions$ 8.996  Millions
Elutia Inc   1.56 $ 28.488  Millions$ 18.225  Millions
Ocugen Inc   1.54 $ 31.855  Millions$ 20.708  Millions

Date modified: 2026-08-30T14:40:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.